Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Free Cash Flow (2023 - 2025)

Historic Free Cash Flow for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $99.8 million.

  • Monte Rosa Therapeutics' Free Cash Flow rose 56640.02% to $99.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $145.0 million, marking a year-over-year increase of 33097.82%. This contributed to the annual value of $38.0 million for FY2024, which is 16048.09% up from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' Free Cash Flow stood at $99.8 million, which was up 56640.02% from -$36.4 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' Free Cash Flow's 5-year high stood at $128.7 million during Q4 2024, with a 5-year trough of -$47.1 million in Q1 2025.
  • Moreover, its 3-year median value for Free Cash Flow was -$29.8 million (2024), whereas its average is -$777454.5.
  • Within the past 5 years, the most significant YoY rise in Monte Rosa Therapeutics' Free Cash Flow was 56640.02% (2025), while the steepest drop was 2224.31% (2025).
  • Over the past 3 years, Monte Rosa Therapeutics' Free Cash Flow (Quarter) stood at $27.9 million in 2023, then surged by 360.69% to $128.7 million in 2024, then fell by 22.5% to $99.8 million in 2025.
  • Its Free Cash Flow stands at $99.8 million for Q3 2025, versus -$36.4 million for Q2 2025 and -$47.1 million for Q1 2025.